<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04847141</url>
  </required_header>
  <id_info>
    <org_study_id>GC2010</org_study_id>
    <secondary_id>2021-000269-34</secondary_id>
    <nct_id>NCT04847141</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients</brief_title>
  <acronym>COVID-19</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of Anti-COVID-19 Immune Globulin (Human) 20% (C19-IG 20%) Versus Placebo in Asymptomatic Ambulatory Outpatients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grifols Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grifols Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the efficacy of anti-COVID-19 immune globulin (human)&#xD;
      20% (C19-IG 20%) (2 doses) versus placebo with regard to the percentage of asymptomatic&#xD;
      participants who remain asymptomatic, i.e., who do not develop symptomatic coronavirus&#xD;
      disease 2019 (COVID-19) through Day 14 as per the protocol defined criteria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Asymptomatic Participants who Remain Asymptomatic, i.e., who do not Develop Symptomatic COVID-19</measure>
    <time_frame>Up to Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load (log10 copies/mL)</measure>
    <time_frame>Day 1 to Day 7, and up to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Remain in an Outpatient Setting and Maintain Peripheral Oxygen Saturation by Pulse Oximetry (SpO2) ≥94% on Room Air</measure>
    <time_frame>Day 3, Day 7, and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Negative for SARS-CoV-2 by Polymerase Chain Reaction (PCR)</measure>
    <time_frame>Up to Day 14, and up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Negative SARS-CoV-2 PCR</measure>
    <time_frame>Baseline up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Require Oxygen (O2) Supplementation</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Any Oxygen</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Value Score on a 7-point Ordinal Scale</measure>
    <time_frame>Day 1, Day 7, Day 14, and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in the 7-point Ordinal Scale</measure>
    <time_frame>Day 1, Day 7, Day 14, and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Each Severity Category of the 7-point Ordinal Scale</measure>
    <time_frame>Day 1, Day 7, Day 14, and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in National Early Warning Score (NEWS)</measure>
    <time_frame>Day 1, Day 7, Day 14, and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Require At Least One COVID-19 Related Medically Attended Visit for Management/Treatment of COVID-19 which may Occur in Any Setting</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Require Hospital Admission for Medical Care (Non-Quarantine Purposes)</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospital Stay</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Require Intensive Care Unit (ICU) Admission or Initiation of ICU Level Care</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU Stay</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring Invasive Mechanical Ventilation</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Invasive Mechanical Ventilation</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with All-Cause Mortality</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Critical COVID-19 Illness</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Time to Clinical Progression to Critical COVID-19 Illness</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">801</enrollment>
  <condition>COVID-19</condition>
  <condition>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection</condition>
  <arm_group>
    <arm_group_label>C19-IG 20% 1 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 gram (g) of C19-IG 20% subcutaneous (SC) infusion containing one syringe of 5 mL C19-IG 20% plus one syringe of 5 mL 0.9% sodium chloride on Day 1 in a double-blind manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C19-IG 20% 2 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 2 g of C19-IG 20% SC infusion containing two syringes 5 mL each of C19-IG 20% on Day 1 in a double-blind manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive C19-IG 20% matching placebo as SC infusion containing two syringes of 5 mL each sterile 0.9% sodium chloride injection on Day 1 in a double-blind manner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>C19-IG 20%</intervention_name>
    <description>Anti-COVID-19 Immune Globulin (Human) 20%</description>
    <arm_group_label>C19-IG 20% 1 g</arm_group_label>
    <arm_group_label>C19-IG 20% 2 g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% Sodium chloride</intervention_name>
    <description>C19-IG 20% matching placebo</description>
    <arm_group_label>C19-IG 20% 1 g</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ambulatory male or female outpatients ≥ 18 years of age who have laboratory-confirmed&#xD;
             severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as determined&#xD;
             by qualitative PCR (reverse transcriptase (RT)-PCR), or other commercial or public&#xD;
             health assay approved by regulatory authorities as a diagnostic test for COVID-19&#xD;
             (inclusive of SARS-CoV-2 antigen testing or other approved rapid testing platforms) in&#xD;
             any specimen ≤ 5 days prior to randomized treatment.&#xD;
&#xD;
          2. Asymptomatic with no constitutional COVID-19 illness (evident symptoms), specifically&#xD;
             no fever, cough, shortness of breath, fatigue, anorexia, vomiting/diarrhea, headache&#xD;
             that is unrelated to pre-existing conditions (example, migraine), sore throat that is&#xD;
             unrelated to other pre-existing medical conditions (example, allergies,&#xD;
             gastroesophageal reflux disease), myalgias, olfactory disorders unrelated with&#xD;
             previous medical condition, or evidence of pneumonia at Screening.&#xD;
&#xD;
          3. Pulse oximetry peripheral oxygen saturation (SpO2) (oxygen saturation) on room air &gt;&#xD;
             94% (i.e., 95% to 100%) at Screening.&#xD;
&#xD;
          4. National Early Warning Score (NEWS) ≤ 2 points at Screening.&#xD;
&#xD;
          5. Subject provides informed consent (ICF) prior to initiation of any study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who are admitted to hospital or for whom hospital admission is being planned&#xD;
             at the time of Screening.&#xD;
&#xD;
          2. Subjects requiring any form of oxygen supplementation at Screening.&#xD;
&#xD;
          3. Concurrent or planned treatment with other agents with actual or possible direct&#xD;
             antiviral activity against SARS-CoV-2 including remdesivir.&#xD;
&#xD;
          4. Prior, concurrent or planned treatment with monoclonal antibodies (mAbs) against&#xD;
             SARS-CoV-2&#xD;
&#xD;
          5. Have participated in a previous SARS-CoV-2 vaccine study OR outside of a study have&#xD;
             received any SARS-CoV-2 vaccine of any kind.&#xD;
&#xD;
          6. Have a history of convalescent COVID-19 plasma treatment at Screening.&#xD;
&#xD;
          7. Fever (temperature ≥38.0° C [≥100.4° F]), measured orally, requirement for&#xD;
             antipyretics to reduce temperature (administered for fever), and/or respiratory&#xD;
             symptoms (cough, dyspnea) at Screening.&#xD;
&#xD;
          8. Clinical evidence of any significant acute or chronic disease that, in the opinion of&#xD;
             the investigator, may place the subject at undue medical risk for study treatment.&#xD;
&#xD;
          9. The subject has had a known (documented) history of serious anaphylactic reaction to&#xD;
             blood, any blood-derived plasma product or commercial immunoglobulin, or has known&#xD;
             selective immunoglobulin A (IgA) deficiency with anti-IgA antibodies.&#xD;
&#xD;
         10. Decompensated congestive heart failure or renal failure with fluid overload. This&#xD;
             includes currently uncontrolled congestive heart failure New York Heart Association&#xD;
             Class III or IV stage heart failure.&#xD;
&#xD;
         11. Subjects for whom there is limitation of therapeutic effort such as &quot;Do not&#xD;
             resuscitate&quot; status.&#xD;
&#xD;
         12. Currently participating in another interventional clinical trial with investigational&#xD;
             medical product or device.&#xD;
&#xD;
         13. Subjects with known (documented) thrombotic complications to polyclonal intravenous&#xD;
             immune globulin (IVIG) therapy in the past.&#xD;
&#xD;
         14. Subject has medical condition (other than COVID-19) that is projected to limit&#xD;
             lifespan to ≤ 1 year.&#xD;
&#xD;
         15. Subject has history of drug or alcohol abuse within the past 12 months.&#xD;
&#xD;
         16. Women who are pregnant or breastfeeding, or if of childbearing potential, unwilling to&#xD;
             practice a highly effective method of contraception (oral, injectable, or implanted&#xD;
             hormonal methods of contraception, placement of an intrauterine device or intrauterine&#xD;
             system, condom, or occlusive cap with spermicidal foam/gel/cream/suppository, male&#xD;
             sterilization, or true abstinence) throughout the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oriol Mitjà, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>omitja@flsida.org, +3493 4978339</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mireia Torres</last_name>
    <phone>+34 93 5710500</phone>
    <email>mireia.torres@grifols.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elsa Mondou</last_name>
    <phone>919 316 2079</phone>
    <email>elsa.mondou@grifols.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CAP Gornal</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08902</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Alemany, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CAP Navàs</name>
      <address>
        <city>Navàs</city>
        <state>Barcelona</state>
        <zip>08670</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Alemany, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CAP Sant Fèlix</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08024</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Corbacho, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Salud Nuestra Señora del Pilar</name>
      <address>
        <city>Alcalá de Henares</city>
        <state>Madrid</state>
        <zip>28801</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Galván, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Salud Presentación Sabio</name>
      <address>
        <city>Móstoles</city>
        <state>Madrid</state>
        <zip>28933</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Galván, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CAP Manso</name>
      <address>
        <city>Barcelona</city>
        <zip>08015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Alemany, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CAP Maluquer Salvador</name>
      <address>
        <city>Girona</city>
        <zip>17002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Alemany, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Salud San Andrés</name>
      <address>
        <city>Madrid</city>
        <zip>28021</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Galván, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Salud Fuentelarreina</name>
      <address>
        <city>Madrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Galván, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Salud Hacienda de Pavones Sureste</name>
      <address>
        <city>Madrid</city>
        <zip>28108</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Galván, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Salud Isla de Oza Noroeste</name>
      <address>
        <city>Madrid</city>
        <zip>28108</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Galván, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Pau i Santa Tecla</name>
      <address>
        <city>Tarragona</city>
        <zip>43003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gemma Flores Mateo, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronavirus disease</keyword>
  <keyword>Severe acute respiratory syndrome coronavirus 2</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Asymptomatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

